APVOHealthcare · BiotechnologyThe 1 Wall Street analysts covering Aptevo Therapeutics, Inc. hold a median 12-month price target of $26 — +1285.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 28 of 100 as at 19 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Aptevo Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (98): Smaller than most of the companies we track.
Momentum (2): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on APVO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +1285.9% from it.
Of the 9 most recent actions, 1 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 23 Sept 2024 | Roth MKM | Maintains | Buy | $15 → $8.00 |
| 13 May 2022 | Piper Sandler | Maintains | Overweight | $69 → $20 |
| 28 May 2021 | Roth Capital | Maintains | Buy | $64 → $50 |
| 25 Nov 2020 | PiperJaffray | Initiates | Overweight | — |
| 25 Nov 2020 | Roth Capital | Initiates | Buy | — |
| 11 Nov 2020 | Piper Sandler | Maintains | Overweight | $32 → $69 |
| 11 Apr 2018 | Roth Capital | Initiates | Buy | — |
| 9 Sept 2016 | Piper Sandler | Initiates | Overweight | — |
| 9 Sept 2016 | PiperJaffray | Initiates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. APVO appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 18 Sept 2026, Aptevo Therapeutics, Inc. returned −94.8% against +16.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 75% of US stocks
Cheaper than 86% of US stocks
Cheaper than 60% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 4% of US stocks
Higher than 2% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Aptevo Therapeutics, Inc. has a market value of $3.3M and an enterprise value of −$2.3M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$26.4M.
Free cash flow in the twelve months to 30 June 2026: −$25.3M.
Trailing P/E: 0.0×; forward P/E: −0.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Aptevo Therapeutics, Inc. employs 33 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Aptevo Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Aptevo Therapeutics announced that its lead candidate mipletamig achieved a 93% clinical benefit rate when used as a triplet therapy in frontline acute myeloid leukemia patients with TP53 mutations.
Why it matters — This result reflects strong preliminary efficacy for Aptevo's lead pipeline candidate in a difficult-to-treat leukemia patient population.
Aptevo Therapeutics announced a 93% clinical benefit rate with its mipletamig triplet in evaluable frontline acute myeloid leukemia patients with TP53 mutations, a difficult-to-treat subpopulation historically responding poorly to treatment. The company noted that remission results nearly double published venetoclax/azacitidine outcomes. The announcement was made on September 3, 2026.
Why it matters — Aptevo watchers would care because these early clinical results suggest the mipletamig triplet may address a notoriously hard-to-treat AML patient population, potentially differentiating the company's lead candidate in a challenging disease setting.
Aptevo Therapeutics reported its second-quarter 2026 financial results and provided a business update. The update highlighted strong clinical progress for mipletamig, including data in frontline acute myeloid leukemia and a path toward Phase 2, the appointment of a Chief Scientific Officer, non-dilutive grant funding advancing its trispecific pipeline, and a 50/50 collaboration with Niowave to pursue radiopharmaceutical therapeutic development.
Why it matters — APVO watchers would note the combination of advancing clinical data, strengthened leadership, non-dilutive funding, and a new partnership as signals of pipeline progress across multiple therapeutic areas.
Aptevo Therapeutics closed a warrant inducement transaction in which holders of its existing common warrants exercised in full for cash to purchase up to 254,922 shares at a reduced exercise price of $4.03 per share, generating approximately $4.5 million in gross proceeds. In exchange, the company issued new unregistered Inducement Warrants to purchase up to 1,274,610 shares at the same exercise price.
Why it matters — APVO watchers would note that the company raised approximately $4.5 million in gross proceeds while issuing additional warrants that could lead to future dilution.
Aptevo Therapeutics announced it entered into warrant inducement agreements with existing warrant holders to exercise their warrants for cash, generating approximately $4.5 million in gross proceeds, and in exchange issued new inducement warrants at a reduced exercise price of $4.03 per share.
Why it matters — The exercise of existing warrants and issuance of new inducement warrants provides the company with additional capital while also potentially diluting existing shareholders.
The 1 Wall Street analysts covering Aptevo Therapeutics, Inc. have a median 12-month price target of $26, with estimates ranging from $21 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 1 analysts covering Aptevo Therapeutics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Aptevo Therapeutics, Inc. 28 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 19 Sept 2026, Aptevo Therapeutics, Inc. ranks 28 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (98 of 100).
No one can know that. What the data says: the median 12-month target from 1 analysts implies +1285.9% from the last close, and Ticker Nerd's factor model ranks Aptevo Therapeutics, Inc. 28 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Aptevo Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for APVO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $21 to $30 over the next 12 months.
Aptevo Therapeutics, Inc. returned -94.8% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapy candidates for cancer.
The most recent item we track (Benzinga, 3 Sept 2026): "Aptevo Therapeutics Reports 93% Clinical Benefit Rate in Key Leukemia Trial". Aptevo Therapeutics announced that its lead candidate mipletamig achieved a 93% clinical benefit rate when used as a triplet therapy in frontline acute myeloid leukemia patients with TP53 mutations.
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapy candidates for cancer. The company uses its proprietary ADAPTIR and ADAPTIR-FLEX platforms to design mono-, bi-, and multi-specific antibody-based therapeutics intended to engage the immune system against tumor cells. Its current pipeline includes candidates for hematologic malignancies and solid tumors, with programs spanning clinical and preclinical development. Aptevo Therapeutics Inc. operates in the oncology and immuno-oncology segments of the healthcare market, where it contributes to the development of targeted biologic therapies for complex cancers. Headquartered in Seattle, Washington, the company concentrates on research-driven product development and collaboration-based innovation in modern cancer treatment.
CEO Mr. Jeffrey G. Lamothe CA · 33 employees · United States · https://aptevotherapeutics.com
